Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMP1734 + paclitaxel
- Development stage
- Unknown
- Lead developer
- IMPACT Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
IMP1734 + paclitaxel is an investigational combination regimen consisting of IMP1734 (also known as EIK1003), an oral, highly selective PARP1 inhibitor, and paclitaxel, an intravenous microtubule-stabilizing taxane chemotherapy. IMP1734 is designed to selectively inhibit PARP1 while sparing PARP2, which is intended to improve the therapeutic index and reduce the hematologic toxicities (such as myelosuppression) typically associated with non-selective PARP1/2 inhibitors. This improved safety profile allows IMP1734 to be combined with cytotoxic chemotherapies like paclitaxel. The combination is being co-developed by IMPACT Therapeutics and Eikon Therapeutics and is currently in Phase 1/2 clinical trials (such as NCT06253130) for the treatment of advanced solid tumors, including epithelial ovarian cancer and HER2-negative breast cancer.
- Other names
- EIK1003 + paclitaxelpaclitaxel + EIK1003paclitaxel + IMP1734
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on IMP1734 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMP1734 + paclitaxel.